Cathepsin-D and outcomes in peripartum cardiomyopathy: Results from IPAC

• DOI: 10.1016/j.ahjo.2024.100489
• Publication Date: 2024-12-09T15:40:35Z
• Authors: Vincenzo B. Polsi...; Karen Hanley-Yanez; Charles F. McTiernan; Kalgi Modi; Jennifer Haythe; Hal Skopicki; Uri Elkayam; Leslie T. Cooper; James D. Fett; Dennis M. McNamara
• Keywords: Peripartum Cardiomyopathy

Evaluate the relationship of cathepsin-D (CD) on disease severity and clinical outcomes for women with peripartum cardiomyopathy. Cathepsin-D is a protease released during oxidative stress that cleaves prolactin (PRL) generating 16 kDa fragment pro-apoptotic, anti-angiogenic, has been implicated in pathogenesis cardiomyopathy (PPCM). In 99 newly diagnosed PPCM enrolled Investigation Pregnancy Associated Cardiomyopathy (IPAC) study, CD levels were assessed by ELISA from serum obtained at study entry. Left ventricular ejection fraction (LVEF) was echocardiography entry, 6, 12-months. compared to healthy PP non-PP controls. Survival free major cardiovascular events (death, transplantation, or left assist device) determined up 12 months post-partum (PP). Mean age 30 ± 6 years, baseline LVEF 34 % 10. higher (278 114 ng/ml) than (190 74, p = 0.02) controls (136 79, < 0.001). There no association age, breastfeeding status, time delivery presentation. New York Heart Association (NYHA) functional class (p Higher tertiles associated lower event-free survival 0.008). this prospective cohort PPCM, diagnosis worse symptoms, less recovery LVEF, outcomes. Circulating may contribute development influence severity, myocardial recovery,